Breast cancer research and treatment

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase.

Breast cancer research and treatment

Sachdev JC, Munster P, Northfelt DW, Han HS, Ma C, Maxwell F, Wang T, Belanger B, Zhang B, Moore Y, Thiagalingam A, Anders C

Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice.

Breast cancer research and treatment

Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL

Family history and risk of breast cancer: an analysis accounting for family structure.

Breast cancer research and treatment

Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.

Breast cancer research and treatment

Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Breast cancer research and treatment

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Breast cancer research and treatment

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ

The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.

Breast cancer research and treatment

Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.

Breast cancer research and treatment

Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman M

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Breast cancer research and treatment

Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T

Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology.

Breast cancer research and treatment

Geyer FC, de Biase D, Lambros MB, Ragazzi M, Lopez-Garcia MA, Natrajan R, Mackay A, Kurelac I, Gasparre G, Ashworth A, Eusebi V, Reis-Filho JS, Tallini G

Pages